SciSparc Ltd., a biotechnology firm specializing in the development of cannabinoid technologies for central nervous system disorders, has announced a significant expansion of its financial instruments. The Tel Aviv-based company, which operates within the global healthcare sector, is set to see a new derivative warrant commence trading on the Stock Exchange of Thailand on 16 November 2026.
The new instrument, issued by KGI Securities, is a call warrant tied directly to SciSparc’s shares. Trading under the symbol SPRC13C2705A, the warrant will be made available to market participants in a substantial number of units. This strategic move is designed to broaden the company’s financing options while simultaneously offering investors new ways to engage with SciSparc’s equity performance.
Under the terms of the issuance, the warrant follows a European-style arrangement for exercise. The exercise price has been established at a level above the current market value of the underlying stock. Investors participating in this instrument will note that the last trading day is scheduled for early May 2027, with the subsequent settlement and distribution dates to follow shortly thereafter.
As a Nasdaq-listed entity, SciSparc Ltd. continues to navigate a volatile market landscape. The company’s stock recently closed at 0.353 USD on 12 November 2026, trading near its 52-week low of 0.345 USD, a significant departure from its 52-week high of 29.88 USD recorded in late 2025. Despite these market fluctuations, the introduction of the SPRC13C2705A warrant represents a proactive effort by the company to diversify its capital structure and provide specialized investment tools to the international market.




